Accelerate oncology research
with SRG Rat – a SCID model
ideal for human xenografts

Schedule A Call


Are you finding it difficult to find the right physiologically -relevant animal model which is able to engraft your cancer xenografts and PDXs?

Our novel SRG Rat model is a unique platform for xenograft and PDX drug efficacy studies.

Created through knockout mutations in the Rag2 and Il2rgamma genes that result in a loss of mature B, T, and NK cells, the SRG Rat has an immunodeficient phenotype ideal for the engraftment of human tissue.

Taking advantage of the Sprague Dawley background and the larger sized xenograft host, the SRG is an ideal model for combining efficacy, pharmacokinetic (PK), biomarker, and toxicology-related endpoints.

Boost your preclinical oncology research with our SRG Rat model delivered directly from our colony maintained at the Charles River Labs GEMS facility at the highest health standard.

Contact us to learn more.

Schedule A Call

What’s Unique About The SRG Rat Model?

While some immunodeficient rodent strains such as the Nude rat are partially immunodeficient missing T-cells, this enhanced immunodeficient rat model has a severely impaired immune system lacking B-cells, T-cells, and NK-cells.

The SRG Rat model demonstrated enhanced utility such as high tumor takes and favorable growth kinetics for both cancer cell-line xenografts and PDX models. The model overcomes the limitations of smaller mouse models enabling larger tumor growth, easier surgeries, and more tissues and serum for analyses, including repeat sampling.

Download Datasheet

Validated Using Difficult Xenograft and Patient Derived Xenograft (PDX) Models

The SRG Rat has been validated using a wide range of xenografts that consistently demonstrate high tumor take rates with traditionally difficult to engraft cell lines, such as VCaP prostate cancer, H358 non-small cell lung cancer (NSCLC), and prostrate, NSCLC, and ovarian PDX models.

Additionally, humane endpoints allow for subcutaneously implanted xenograft and PDX models to reach 10X tumor volumes, up to >20,000 mm3, compared to mouse xenografts allowing for serial tumor sampling or faster PDX establishment.

Download Datasheet

How Is The SRG Rat Better Than SCID Mice?

Through the use of the SRG Rat, researchers can collect more consistent, higher quality data that provides advantages for predicting success in the clinic.

Xenografts in the larger SRG Rat models can display vastly improved engraftment efficiencies, tumor size, growth, and tumor morphology across a number of human cancer cell lines and patient-derived tissues that are either not permissive or extremely inefficient in mice.

An added benefit is the ability of the rat to achieve more human-like physiologic and metabolic traits versus mice.

Download Datasheet

Cancer Researchers Find Success With SRG Rat Models

A team of researchers led by Dr. Ramesh Narayanan at the University of Tennessee partnered with Hera BioLabs to evaluate new therapeutics for castration-resistant prostate cancer (CRPC), targeting androgen receptors (ARs).

Given the need for prostate cancer xenografts which model high AR-expression amplification phenotype found in many CRPC patients, the SRG rat has high tumor take rates of prostate cancer xenograft cell lines such as LNCaP & VCaP (>90%) which are prohibitively inefficient in mouse. Hera has expanded our capabilities to include validated castration-resistant and enzalutamide-resistant models.

Learn more by downloading our case study.

Download Case Study

Accelerate Your Pre-Clinical Cancer Research and Drug Development

Contact us to learn more about our SRG Rat for oncology research.

Schedule A Call
Download Datasheet
Download Case Study